139-29-7

Usage

Uses

Used in Chemical Synthesis:
3',4-dinitrobenzanilide is used as a key intermediate in the synthesis of various organic compounds, contributing to the development of new chemical entities with potential applications across different industries.
Used in Dye and Pigment Production:
In the dye and pigment industry, 3',4-dinitrobenzanilide is utilized as a starting material for the production of a range of dyes and pigments, enhancing color options and performance characteristics for various applications.
Used in Pharmaceutical Industry:
3',4-dinitrobenzanilide plays a crucial role in the pharmaceutical sector as a precursor for the synthesis of diverse pharmaceutical products, aiding in the development of new medications and therapeutic agents.
Used in Research:
As a research chemical, 3',4-dinitrobenzanilide is employed in scientific studies to explore its properties and potential applications, contributing to the advancement of knowledge in the field of chemistry.
Safety Note:
Due to its moderately toxic nature, it is essential to handle 3',4-dinitrobenzanilide with proper care and implement appropriate safety measures when working with it in a laboratory setting.

Upstream product

• 122-04-3 4-nitro-benzoyl chloride 
• 99-09-2 3-nitro-aniline 
• 1429-05-6 phenyl 4-nitrobenzoate 
• 62-23-7 4-nitro-benzoic acid 

Downstream Products

• 2657-85-4 4-amino-N-(3-aminophenyl)benzamide 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of small-molecular di-basic esters, amides and carbamates as flaviviral protease inhibitors

Inhibitors of the flaviviral serine proteases, which are crucial for the replication of dengue and West-Nile virus, have attracted much attention over the last years. A dibasic 4-guanidinobenzoate was previously reported as inhibitor of the dengue protease with potency in the low-micromolar range. In the present study, this lead structure was modified with the intent to explore structure-activity relationships and obtain compounds with increased drug-likeness. Substitutions of the guanidine moieties, the aromatic rings, and the ester with other functionalities were evaluated. All changes were accompanied by a loss of inhibition, indicating that the 4-guanidinobenzoate scaffold is an essential element of this compound class. Further experiments indicate that the target recognition of the compounds involves the reversible formation of a covalent adduct.

Biological evaluation and molecular docking studies of nitro benzamide derivatives with respect to in vitro anti-inflammatory activity

A series of nitro substituted benzamide derivatives were synthesized and evaluated for their potential anti-inflammatory activities in vitro. Firstly, all compounds (1–6) were screened for their inhibitory capacity on LPS induced nitric oxide (NO) production in RAW264.7 macrophages. Compounds 5 and 6 demonstrated significantly high inhibition capacities in a dose-dependent manner with IC50 values of 3.7 and 5.3 μM, respectively. These two compounds were also accompanied by no cytotoxicity at the studied concentrations (max 50 μM) in macrophages. Molecular docking analysis on iNOS revealed that compounds 5 and 6 bind to the enzyme more efficiently compared to other compounds due to having optimum number of nitro groups, orientations and polarizabilities. In addition, 5 and 6 demonstrated distinct regulatory mechanisms for the expression of the iNOS enzyme at the mRNA and protein levels. Specifically, both suppressed expressions of COX-2, IL-1β and TNF-α significantly, at 10 and 20 μM. However, only compound 6 significantly and considerably decreased LPS-induced secretion of IL-1β and TNF-α. These results suggest that compound 6 may be a multi-potent promising lead compound for further optimization in structure and as well as for in vivo validation studies.

Design, synthesis and structure-activity relationship of new HSL inhibitors guided by pharmacophore models

Hormone-sensitive lipase (HSL) is a critical enzyme involved in the hormonally regulated release of fatty acids and glycerol from adipocyte lipid stores. Its inhibition may improve insulin sensitivity and blood glucose handling in type 2 diabetes. Accordingly, many small-molecule HSL inhibitors have recently been identified. In continuation of our efforts for discovery of new HSL inhibitors, we prepared a variety of esters, amides, sulfonamides and sulfonate esters capable of fitting two pharmacophore models that we developed and published earlier. The tested compounds were synthesized via coupling reactions of aroyl chlorides or sulfonyl chlorides with phenols, amines and related derivatives. Our efforts led to the identification of interesting compounds of low micromolar anti-HSL bioactivities, which have potential to be developed into effective antidiabetic agents.

Substituted cyclic amine compound, production process thereof and pharmaceutical composition for circulatory organ use containing the same

A substituted cyclic amine compound represented by the following general formula (1) STR1 wherein each of R1 to R5 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or the like, A represents a carbonyl group or a sulfonyl group, B represents a methine moiety or a nitrogen atom, D represents a methine moiety, a nitrogen atom or =N(→O)-- and n is an integer of 2 to 3; and synthetic methods thereof. The inventive compound is useful in preventing and treating circulatory organ-related diseases such as hypertension, ischemic heart disease, cerebrovascular disease, peripheral circulatory disease and the like.